BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 24, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2011

View Archived Issues

SPINK1 identified as potential therapeutic target in prostate cancer

Read More

GSK-3 inhibitor SC-001 may have potential for the treatment of Parkinson's disease

Read More

Neuroprotective efficacy hypothesized for Klotho enhancers

Read More

New dual DPP IV/AP-N inhibitors prepared by IMTM

Read More

Research Development Foundation patents novel urocortin-2 analogues

Read More

New B-raf inhibitors reported by Array BioPharma and Genentech

Read More

Lilly and Avid receive FDA complete response letter for Amyvid

Read More

Vardenafil plus tamsulosin improves LUTS in subjects with BPH in long-term study

Read More

CHMP recommends approval of Lucentis in new indication

Read More

Nerviano enters into oncology license agreement with Novartis

Read More

CHMP adopts negative opinion for Vectibix in combination with chemotherapy

Read More

Insys Therapeutics reports phase III data for fentanyl sublingual spray

Read More

Lonza and Athera sign development and manufacturing agreement for PC-mAb

Read More

Scientists at Anacor Pharmaceuticals prepare new antiprotozoal agents

Read More

Regeneron and sanofi-aventis begin phase II trial of MAb SAR-231893 in eosinophilic asthma

Read More

University of Pennsylvania designs novel adamantane analogues for influenza and related disorders

Read More

Euthymics Bioscience begins EB-1010 trial for major depression

Read More

KAI Pharmaceuticals begins enrollment of phase II study of KAI-4169 in secondary hyperparathyroidism

Read More

Polaris begins enrollment in phase II trial of ADI-PEG 20 in malignant mesothelioma

Read More

KineMed extends collaboration with Bristol-Myers Squibb for Alzheimer's disease

Read More

Genentech's pivotal trial of vismodegib in advanced basal cell carcinoma meets primary endpoint

Read More

CHMP adopts positive opinion regarding new birth control pill NOMAC/E2

Read More

Septodont acquires local anesthesia reversal agent OraVerse from Novalar

Read More

Quark terminates phase II study of PF-04523655 early, plans phase IIb study

Read More

Cell Therapeutics opens enrollment in pivotal PIX-R trial of pixantrone

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 23, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing